Brand name : Pomalid
Active ingredient : Pomalidomide
Manufactured : Natco Pharma
Strength : 2mg
Pack : 21 capsules in a container
Category : Anti-neoplastic drug
Pomalid(pomalidomide) 2mg is a Natco pharma product which is endorsed by FDA, containing an active anti-cancer drug called pomalidomide. Pomalid(pomalyst) 2mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomalid(pomalidomide) 2mg is similar to thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may leads to severe liver injury. Pomalid(pomalyst) 2mg is involved in the treatment for regression & unmanageable multiple myeloma. Pomalid(pomalidomide) 2mg is used in the patients who are failing to response for Lenalidomide treatment. Pomalid(pomalyst) 2mg is used in combination with dexamethasone.
The major therapeutic indication of Pomalid 2mg is involved in the treatment of multiple myeloma. This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomalid(pomalyst) 2mg pomalidomide. Pomalid(pomalidomide) 2mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.
During hematological toxicities
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomalid therapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomalid 3mg daily.
Platelets count <25,000/mcL: postpone the Pomalid treatment & follow the CBC >50,000/mcL: continue 3mg of Pomalid
Pomalid(pomalidomide) 2mg with potent CYP1A2 inhibitor :
During this combination reduce the dose of Pomalid(pomalyst) by 50%
In renal impairment :
Initial dose of Pomalid is 3mg
In hepatic impairment :
Mild to moderate condition, an initial dose of Pomalid(pomalyst) is 3mg; in severe condition, the initial dose of Pomalid(pomalidomide) is 2mg.
Pomalid(pomalidomide) 2mg WORKS
Pomalid(pomalyst) 2mg exhibits various activities like;
Prohibits proliferation Promote apoptosis of hematopoietic cancer cells Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis
Prohibits proliferation Boosted the T-cells & natural killer cell mediate immunity. The drug is prohibited the formation of pro-inflammatory cytokines by monocytes.
Prohibits proliferation Interfere with formation of new vessels and leads to inhibit the cell division.
There are two major worsening condition may occur during the treatment using with Pomalid 2mg.
Embryo fetal damage
Pomalid(pomalidomide) 2mg capsules are contraindicated to pregnancy period. During the treatment, patients avoid to becoming pregnant. Use effective contraceptives for preventing pregnancy during therapy.
Venous & arterial thromboembolism
Patient who are receiving Pomalid(pomalidomide) 2mg capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke. This type of condition should be treated by initiating prophylactic anti-thrombotic drugs. The patients who are acquiring this condition then thromboprophylaxis should be provided
Pomalidomide? metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomalid(pomalidomide) 2mg with CYP1A2 drugs like Fluoxamine causes elevation of Cmax & AUC of Pomalidomide and concludes as increased concentration of Pomalid leads to higher extent of adverse effects associated with Pomalid In this condition, reduce the dose of Pomalid 2mg and recommended.
Pomalid 2mg should be contraindicated to pregnancy & lactating women. The pregnancy category of Pomalid(pomalyst) 2mg is X.